Division of Sanofi
Latest From Acambis PLC
There are two factors that limit the ability of the Ebola virus to become a global public health tragedy: its inefficient method of transmission between humans; and its natural reservoir, which seems to be bats located in distal east Africa. These and other facets of the disease paradoxically make the Ebola virus a positive public relations opportunity for big pharmaceutical companies, but a loss-making opportunity for their small biotechnology brethren.
In the past eight years (2006-2013), the global pharmaceutical and biotechnology industry has spent at least $930bn on drug research and development, according to data Scrip has accumulated from publicly-available company information.
As more biopharmaceutical companies become profitable and global, tax strategy becomes an increasingly important aspect of deal-making and intellectual property management. Deals of the Week looks at recent tax winners, new tax tactics and potential deal targets that are attractive in part because of their high – or low – tax rates.
BioNet-Asia has carved a path in vaccines research in Thailand that faces the hurdle of attracting private funding while working on establishing proof of concept for pertussis and dengue vaccines. A mix of private capital and multinational alliances have helped nations such as Vietnam, Indonesia and Malaysia build up domestic vaccine capabilities.
- Therapeutic Areas
- Infectious & Viral Diseases
- Peptide Therapeutics Group PLC
- Western Europe
- Parent & Subsidiaries
- Senior Management
Elizabeth Jones, CFO
Michael Watson, PhD, EVP, R&D
- Contact Info
Phone: (44) 1223 275 300
100 Fulbourn Rd.
Cambridge, CBI 9PT
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.